Moderna updates cash consumption guidance, advances Covid vax candidate

Moderna (MRNA) Q2 results:

Revenues: $66.4M (+406.9%).

Net loss: ($116.7M) (+13.5%); loss/share: ($0.31) (+24.4%).

CF Ops: $130.1M (-48.6%).

The company updates 2020 guidance to reflect investments into mRNA-1273. Net cash used in operating activities is expected between $0.65B to $0.85B.

Phase 2 study of COVID-19 vaccine candidate (mRNA-1273) fully enrolled; Phase 3 study in collaboration with NIH and BARDA is on track to complete enrollment in September 2020.

https://seekingalpha.com/news/3600800-moderna-updates-cash-consumption-guidance-advances-covidminus-19-vaccine-candidate